Front Pharmacol. 2024 Dec 18:15:1464852.doi: 10.3389/fphar.2024.1464852. eCollection 2024. (IF:5.6).
2024-12-18Front Pharmacol. 2024 Dec 18:15:1464852.doi: 10.3389/fphar.2024.1464852. eCollection 2024. Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC 转录因子MEF2D调节ACSL3的异常表达,并通过抑制肝细胞癌中的铁下垂来增强索拉非尼的耐药性 (IF:5.6).